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ORIGINAL ARTICLE
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Abstract
Objective: To clarify the efficacy and safety of abatacept for secondary Sjo¨gren’s syndrome (SS)
associated with rheumatoid arthritis (RA).
Methods: The primary endpoint of this open-labeled, prospective, observational multicenter
study for secondary SS with RA was the remission rate of Simplified Disease Activity Index (SDAI)
at 52 weeks after initiation of abatacept. The secondary endpoints included Saxon’s test and
Schirmer’s test. Adverse events and adherence rate during the study period were also analyzed.
Results: Thirty-six patients (all females) were enrolled in this study. The mean SDAI decreased
significantly from 20.6 ± 11.2 (±SD) at baseline to 10.0 ± 10.5 at 52 weeks (p50.05). Patients
with SDAI remission increased from 0 (0 week) to 12 patients (33.3%) at 52 weeks. Saliva
volume assessed by Saxon’s test increased significantly from 2136 ± 1809 (0 week) to
2397 ± 1878 (24 weeks) mg/2min (n¼ 34, p50.05). Saliva volume increased significantly from
2945 ± 2090 (0 week) to 3419± 2121 (24 weeks) mg/2min in 11 patients with Greenspan grade
1 or 2 of labial salivary gland biopsy (p50.05), but no change was noted in 18 patients with
Greenspan grade 3 or 4. Tear volume by Schirmer’s test increased significantly from 4.2 ± 4.8 (0
week) to 6.4 ± 7.8 (24 weeks) mm/5min (n¼ 30, p50.05). The adherence rate to abatacept was
80.6% (29/36) over the 52-week period. Twelve adverse events occurred in 10 of the
36 patients, and 7 of these events were infections.
Conclusion: Abatacept seems to be effective for both RA and SS related manifestations.
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Introduction
Sjo¨gren’s syndrome (SS) is an autoimmune disease characterized
pathologically by lymphocytic infiltration into the exocrine glands
(including salivary and lacrimal glands) and clinically by dry mouth
and dry eyes. SS is classified into primary SS, which is not asso-
ciated with any other well-defined connective tissue disease (CTD),
and secondary SS, which is associated with other well-defined
CTD [1]. With regard to secondary SS, all-Japan survey on the
epidemiology of SS showed previously that secondary SS was
associated with rheumatoid arthritis (RA) in 38.7% of the cases, and
systemic lupus erythematosus (SLE) in 22.2% [2]. These data high-
light the clinical importance of secondary SS associated with RA.
Various types of biologics that target immune cells, cytokines,
and cytokine receptors have been introduced for the treatment of
diverse autoimmune diseases such as RA, SLE, inflammatory
bowel disease, psoriasis, and systemic vasculitis [3–7]. Although
the usefulness of biologics for SS has not been established yet, the
most encouraging results were obtained from randomized
controlled trials (RCTs) of rituximab, a B cell targeting biologic,
including its efficacy in the control of the disease especially for
extra-glandular manifestations [8–11]. However, a more recent
large RCT of rituximab (TEARS trial) demonstrated that rituximab
failed to improve glandular and extra-glandular manifestations of
SS [12]. Thus, while the efficacy of rituximab against extra-
glandular involvements of SS has been suggested, its usefulness
for glandular involvements is controversial at present.
With regard to other biologics, TNF inhibitors (infliximab and
etanercept) are reported to have no significant effects on glandular
or extra-glandular manifestations of SS [13,14]. Although B cell
activating factor (BAFF) is a promising biologic for SS,
belimumab, a monoclonal anti-BAFF antibody, did not improve
salivary flow or lacrimation, although it significantly decreased a
composite of disease activity measures, including the European
League Against Rheumatism (EULAR) Sjo¨gren’s Syndrome
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Disease Activity Index (ESSDAI) and EULAR Sjo¨gren’s
Syndrome Patient Reported Index (ESSPRI) [15]. Another phase
III RCT is currently being conducted to examine the effects of
tocilizumab, a monoclonal anti-IL-6 receptor antibody, versus
placebo, in SS patients [8].
The effects of T cell-targeting biologic, abatacept (CTLA4-Ig),
on SS were examined recently. Abatacept was designed for the
treatment of SS manifestations based on the pathogenic role of
CD4+ T cells in SS [16,17]. Actually, two open label pilot studies
have so far examined the effectiveness of abatacept in primary SS
[18,19]. Adler et al. [18] showed that abatacept significantly
reduced salivary gland inflammation, and increased saliva pro-
duction when the dose was adjusted for disease duration. Meiners
et al. [19] reported that while abatacept improved ESSDAI,
ESSPRI, and laboratory tests in patients with early and active
primary SS, it had a minor beneficial effect on preservation of
salivary and lacrimal gland functions. Furthermore, we designed
an open-labeled, 1-year, prospective, observational, and multi-
center study (ROSE trial; Rheumatoid Arthritis with Orencia Trial
toward Sjo¨gren’s syndrome Endocrinopathy) to establish the
efficacy and safety of abatacept in secondary SS patients
associated with RA [20]. Interim analysis of 32 patients from
the ROSE trial after 24 weeks of treatment demonstrated that
abatacept improved both SS and RA manifestations of secondary
SS with RA. With accumulation of more data, we present in this
report the results of 36 patients after 52 weeks of ROSE trial.
Patients and methods
Patients
Patients aged more 20 years diagnosed with RA according to
the American College of Rheumatology (ACR) 1987 [21] or
ACR/EULAR 2010 criteria [22], and SS according to the 1999
Japanese Ministry of Health criteria for the diagnosis of SS
[23], who presented with sicca symptoms were eligible for this
study. The 1999 Japanese Ministry of Health criteria for the
diagnosis of SS include the presence of two or more of the
following four clinicopathological findings: (1) lymphocytic
infiltration of the salivary or lacrimal glands, (2) dysfunction of
salivary glands, (3) keratoconjunctivitis sicca (KCS), and (4)
presence of anti-SS-A or SS-B antibodies [23]. The patients
were followed up at the Departments of Rheumatology of three
hospitals in Japan (University of Tsukuba hospital, University
of Occupational and Environmental Health hospital, and
Nagasaki University hospital). Approval for this study was
obtained from the local ethics committees of each study site
and a signed informed consent was obtained from each subject
(approval number of University of Tsukuba: H23-29, certifica-
tion date of approval: July 28, 2011). This study was registered
at the University Hospital Medical Information Network
(UMIN)-Clinical Trials Registry (CTR) (UMIN-ID:
UMIN000005724).
Patients with contraindications for abatacept (e.g. hypersensi-
tivity, severe infection, and hepatitis B virus infection), aged more
than 75 or less than 20 years, leukopenia (leukocyte count 3000/
mm2), severe liver or kidney diseases, severe hematological
disorders, negative for both anti-SS-A and SS-B antibody and
positive for anti-centromere antibody were excluded from this
study. Patients who were pregnant, nursing, wanted to get
pregnant, and those treated with palliative therapies for dryness
including cevimeline, anetholtritione, and pilocarpine within the
last 4 weeks were also excluded. We also excluded patients who
were considered not suitable for this study by the attending
physician.
Table 1. Baseline clinicopathological features of the 36 enrolled patients.
Age (years) 54.9 ± 14.0
Sex (males/females) 0/36
RA disease duration (months) 116.5 ± 137.5
RA stage (I/II/III/IV) 8/18/4/6
RA functional class (1/2/3/4) 11/22/3/0
DAS28-ESR/DAS28-CRP (n¼ 36) 4.6 ± 1.2/3.7 ± 1.1
SDAI/CDAI (n¼ 36) 20.6 ± 11.2/19.6 ± 11.3
IgG (mg/dl) (n¼ 36) 1805± 525
RF-positive (n¼ 36) 32 (88.9%)
Anti-CCP antibody-positive (n¼ 32) 25 (78.1%)
Anti-SS-A antibody-positive (n¼ 35) 29 (82.9%)
Anti-SS-B antibody-positive (n¼ 32) 4 (12.5%)
Organ involvement
Interstitial lung disease (n¼ 36) 4 (11.1%)
Others (n¼ 36) 4 (11.1%) (kidney 2, AR 1, PBC 1)
Saxon’s test (mg/2min) (n¼ 34) 2136± 1809
Schirmer’s test (mm/5min) (n¼ 30) 4.2 ± 4.8
Greenspan grade in LSG (grade 1/2/3/4) (n¼ 31) 8/4/11/8
MRI of parotid glands (grade 1/2/3/4) (n¼ 12) 3/5/2/2
Corticosteroid use and mean dose (mg/day) (n¼ 36) 17 (47.2%) Equivalent dose of PSL 5.1 ± 2.6
MTX use and mean dose (mg/week) (n¼ 36) 27 (75.0%) 9.3± 3.9
DMARDs other than MTX (n¼ 36) 11 (30.6%)
Previous biologics (n¼ 36) 19.4% (Bio-switch 7, Bio-naı¨ve 29) (including overlap)
IFX 5
ETN 3
ADA 2
TCZ 1
GLM 0
CER 0
Left column: n represents number of patients tested. RA, rheumatoid arthritis; DAS28, disease activity score; SDAI,
Simplified Disease Activity Index; CDAI, Clinical Disease Activity Index; AR, aortic regurgitation; PBC, primary biliary
cirrhosis; LSG, labial salivary gland; MTX, methotrexate; DMARDs, disease-modifying anti-rheumatic drugs; IFX,
infliximab; ETN, etanercept; ADA, adalimumab; TCZ, tocilizumab; GLM, golimumab; CER, certolizumab.
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Medications
The dosing regimen approved for the treatment of RA was used in
this study. The weight-adapted dose of abatacept (500mg for
patients weighing less than 60 kg, and 750mg for those weighing
60 kg) was administrated intravenously at weeks 0, 2, and 4,
every 4 weeks, over a period of 1 year. Other disease-modifying
anti-rheumatic drugs (DMARDs), corticosteroids, and non-ster-
oidal anti-inflammatory drugs were allowed to be used during the
1-year treatment period based on the clinical judgment of the
attending physician.
Analysis of efficacy of abatacept
ROSE trial was designed as an open-labeled, 1-year, prospective,
and observational study. For RA manifestations, the number of
tender and swollen joints among 28 joints, physicians’ global
visual analog scale (VAS), patients’ global VAS, Simplified
Disease Activity Index (SDAI), disease activity score (DAS)
28-erythrocyte sedimentation rate (ESR) and C-reactive protein
(CRP), serum CRP, ESR, and rheumatoid factor (RF) were
assessed at weeks 0 (baseline), 4, 12, 24, and 52. For SS
manifestations, patients’ VAS for dry mouth, dry eye, and parotid
pain, physicians’ VAS for dry mouth, KCS, and general condition,
saliva volume by Saxon’s test, tear volume by Schirmer’s test,
anti-SS-A/SS-B antibody, and serum IgG level were examined at
weeks 0, 12, and 24. Because assessment for SS manifestations
requires the examinations by ophthalmologists and has some
limitations of availability in observational study, we excluded the
assessment for SS manifestations at week 52 in this study. When
available, magnetic resonance imaging (MRI) of parotid glands
was also performed at weeks 0 and 52. Findings of parotid MRI by
T1-weighted and short inversion time inversion recovery (STIR)
sequence were visually evaluated and classified into five grades
according to the methods reported previously by our group [24].
Briefly, we assessed the degree of high-intensity areas on
T1-weighted image (T1WI) and STIR image; grade 0: homogen-
ous signal intensity on T1WI and no focal high intensity spots on
STIR images; grade 1: sparse high signal intensity areas on T1WI
and no focal high intensity spots on STIR images; grade 2: sparse
high signal intensity areas on T1WI and presence of focal high
intensity spots on STIR images; grade 3: moderate high signal
intensity areas on T1WI images and presence of focal high
intensity spots on STIR images; and grade 4: diffuse high signal
intensity area on T1WI and no focal high intensity spots on STIR
images [24].
The primary endpoint was the percentage of patients who
achieved clinical remission by SDAI at 52 weeks. Secondary
endpoints included CRP, ESR, RF, Saxon’s test, Schirmer’s test,
Figure 1. Effects of abatacept on RA. (A) Effects of abatacept treatment
on SDAI in 36 patients. Data deficit was compensated by the LOCF
method. *p50.05 versus 0 week (baseline), Wilcoxon signed-rank test.
ABT, abatacept. (B) Effects of abatacept treatment on SDAI in 7 bio-
switch patients and 29 bio-naı¨ve patients. Data deficit compensated by the
LOCF method. *p50.05 versus 0 week (baseline), Wilcoxon signed-rank
test. The difference between two groups was examined by Mann–Whitney
U test. ABT, abatacept, NS, not significant. (C) Effects of abatacept and
MTX combination treatment on SDAI in 27 patients and of abatacept
alone in 9 patients. Data deficit was compensated by the LOCF method.
*p50.05 versus 0 week (baseline), Wilcoxon signed-rank test. The
difference between two groups was examined by Mann–Whitney U test.
ABT, abatacept, NS, not significant.
Figure 2. Effects of abatacept treatment on RA disease activity. (A)
Effects of abatacept treatment on disease activity as assessed by SADI in
36 patients over the 52-week period. Data deficit was compensated by the
LOCF method. (B) Effects of abatacept treatment on disease activity as
assessed by SDAI in 7 bio-switch patients and 29 bio-naı¨ve patients. Data
deficit was compensated by the LOCF method. Difference between two
groups was examined by Cochran-Armitage Test. There was no significant
difference between the groups. (C) Effects of abatacept and MTX
combination treatment on disease activity as assessed by SDAI in 27
patients and of abatacept alone in 9 patients. Data deficit was compensated
by the LOCF method. Difference between two groups was examined by
Cochran-Armitage Test. There was no significant difference.
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anti-SS-A/SS-B antibody, IgG, patients’ VAS, physicians’ VAS,
and parotid MRI.
Analysis for safety of abatacept
Adverse events (AEs) during the 52-week study period were
analyzed at each visit. The type of AEs, onset, use of corticoster-
oids, treatment for AEs, hospital admission, cessation of use of
abatacept, association with abatacept, and outcome were recorded.
We also recorded the adherence rate to abatacept for 52 weeks and
causes of discontinuation of abatacept.
Statistical analysis
Data are expressed as mean±SD. Differences between baseline
and after treatment with abatacept were examined for statistical
significance using the Wilcoxon signed-rank test. Differences
between groups were examined using the Mann–Whitney U test
for continuous variables, and Cochran-Armitage Test for disease
activity as assessed by SDAI. Correlation between variables was
assessed by Spearman’s rank correlation. A p value less than 0.05
denoted the presence of a statistically significant difference. The
adherence rate to abatacept was analyzed by Kaplan–Meier
method. The deficit of data was compensated by the last
observation carried forward (LOCF) method.
Results
Clinicopathological features at baseline
Thirty-six patients (all females) were enrolled in this study. The
baseline clinicopathological features of the 36 patients are
summarized in Table 1. The mean age was 54.9 ± 14.0 years
and RA disease duration was 116.5± 137.5 months. More than
half of the patients were assessed as Stage I or II, and Class 1 or 2
(Steinbrocker classification). The RA disease activity assessed by
DAS28 and SDAI was moderate. For SS manifestations, salivary
volume assessed by Saxon’s test was 2136± 1809mg/2min
(n¼ 34), tear volume by Schirmer’s test was 4.2± 4.8mm/5min
(n¼ 30), Greenspan grading of labial salivary gland (LSG) biopsy
was grade 1 or 2 in 12 patients, and grade 3 or 4 in 19 patients.
MRI of the parotid glands was performed in 12 patients at
baseline, showing grade 1 in 3 patients, grade 2 in 5 patients, grade
3 in 2 patients, and grade 4 in 2 patients. Corticosteroids were used
in 17 of 36 (47.2%) patients, and the mean equivalent dose of
prednisolone (PSL) was 5.1 ± 2.6mg/day. Methotrexate (MTX)
was administered in 75% of patients (27/36 patients), at a mean
Figure 4. Effects of abatacept on secretory function in SS. (A) Effects of
abatacept treatment on saliva volume assessed by Saxon’s test in 34
patients. Data deficit was compensated by the LOCF method. *p50.05
versus 0 week (baseline), Wilcoxon signed-rank test. ABT, abatacept. (B)
Effect of abatacept treatment on saliva volume assessed by Saxon’s test in
11 patients with Greenspan grading 1 or 2 of LSG biopsy and in 18
patients with grade 3 or 4. Data deficit was compensated by the LOCF
method. *p50.05 versus 0 week (baseline), Wilcoxon signed-rank test.
The difference between the two groups was examined by Mann–Whitney
U test. ABT, abatacept; NS, not significant. (C) Effects of abatacept
treatment on tear volume assessed by Schirmer’s test in 30 patients. Data
deficit was compensated by the LOCF method. *p50.05 versus 0 week
(baseline), Wilcoxon signed-rank test. ABT, abatacept.
Figure 3. Effects of abatacept on VAS in SS. (A) Effects of abatacept
treatment on patients’ VAS for dry mouth, dry eye, and parotid pain in 33
patients. Data deficit was compensated by the LOCF method. *p50.05
versus 0 week (baseline), Wilcoxon signed-rank test. VAS, visual analog
scale, NS, not significant. (B) Effects of abatacept treatment on
physicians’ VAS for dry mouth, KCS, and general condition in 32
patients. Data deficit was compensated by the LOCF method. *p50.05
versus 0 week (baseline), Wilcoxon signed-rank test. VAS, visual analog
scale; KCS, keratoconjunctivitis sicca.
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dose of 9.3± 3.9mg/week. Furthermore, 19.4% of the patients (7/
36 patients) were treated previously with biologics other than
abatacept, while 29 patients were biologics-naı¨ve. Collectively, the
enrolled patients had secondary SS with moderate dryness, in
addition to moderately active established RA.
Effectiveness of abatacept against RA
Disease activity of RA assessed by SDAI significantly decreased
after treatment with abatacept from 20.6± 11.2 (0 week,
baseline) to 10.0 ± 10.5 (52 weeks) (p50.05). Significant
reduction of SDAI relative to baseline (p50.05) was noted at
4 weeks, and maintained over the 52-week period (Figure 1A).
Comparison of bio-switch patients with bio-naı¨ve patients
showed significant improvements in SDAI after initiation of
abatacept in both groups (p50.05) (Figure 1B). Although the
disease activity by SDAI was higher in bio-switch patients than
in bio-naı¨ve patients, there was no significant difference between
the two groups at each time point (Figure 1B). We also
examined the effect of concomitant use of MTX. SDAI
decreased significantly in patients treated with the combination
of abatacept and MTX (p50.05) (Figure 1C). In comparison,
only a moderate decrease was noted in SDAI of patients who
were not treated with MTX (Figure 1C).
Patients with clinical remission, as assessed by SDAI, increased
from 0 patient at 0 week to 12 patients (33.3%) at 52 weeks
(Figure 2A). In contrast, the number of patients with moderate or
high disease activity, as assessed by SDAI, decreased from 26
patients (72.2%) at 0 week to 13 patients (36.1%) at 52 weeks
(Figure 2A). More bio-naı¨ve patients achieved clinical remission
by SDAI at 52 weeks than bio-switch patients, though the
difference between the groups was not statistically significant
(Figure 2B). Comparison between patients treated with and
without MTX showed no statistically significant difference in
disease activity as assessed by SDAI over the 52-week period
(Figure 2C). These findings confirmed the effectiveness of
abatacept against RA manifestations in patients with secondary
SS with RA.
Effectiveness of abatacept against SS
Abatacept significantly reduced the patients’ VAS values for dry
mouth and dry eye from 49.8± 26.5 and 36.5± 28.3mm at 0 week
to 39.5 ± 31.3 and 29.5± 25.5mm at 24 weeks (p50.05, n¼ 33),
respectively (Figure 3A). However, abatacept did not improve
the VAS values for parotid pain (Figure 3A). Abatacept signifi-
cantly decreased physicians’ VAS values for dry mouth, KCS,
and general condition from 42.7± 22.5, 42.3 ± 27.3, and
34.6± 19.0mm at 0 week to 14.7 ± 22.6, 31.0± 25.5, and
24.7± 22.5mm at 24 weeks (p50.05, n¼ 32), respectively
(Figure 3B).
Saliva volume by Saxon’s test significantly increased from
2136± 1809mg/2min at 0 week to 2397± 1878mg/2min at 24
weeks (n¼ 34, p50.05) (Figure 4A). Interestingly, in 11
patients with Greenspan grade 1 or 2 of LSG biopsy, saliva
volume was significantly higher at 24 weeks (3419± 2121mg/
2min) compared with 2945± 2090mg/2min at 0 week
(p50.05), whereas no change was noted in 18 patients with
Greenspan grade 3 or 4 (Figure 4B). Tear volume by Schirmer’s
test was significantly higher at 24 weeks (6.4 ± 7.8mm/5min),
compared with 4.2 ± 4.8mm/5min at 0 week (n¼ 30, p50.05)
(Figure 4C).
Changes in parotid MRI from 0 to 52 weeks were
investigated in six patients. In four of these patients, the
MRI grade of the parotid gland did not change, though it
deteriorated in one and improved in the other (Table 2).
Figure 5. Effects of abatacept on IgG, RF, and anti-SS-A antibody.
Effects of abatacept treatment on (A) serum IgG level (n¼ 36), (B) serum
RF level (n¼ 35). (C) Titer of anti-SS-A antibody (n¼ 22). Data deficit
was compensated by the LOCF method. *p50.05 versus 0 week
(baseline); NS, not significant versus baseline, Wilcoxon signed-rank
test. ABT, abatacept.
Table 2. Changes in parotid MRI and correlation with Greenspan grading of LSD biopsy and salivary secretion.
Parotid MRI Greenspan grading of LSG Salivary secretion by Saxon’s test (mg/2min)
Cases 0 week 52 weeks Change baseline 0 week 52 weeks Change
1 3 3 0 4 560 1140 580
2 1 0 1 1 3840 4490 650
3 1 1 0 1 4500 4430 70
4 2 2 0 3 1260 3630 2370
5 2 2 0 1 810 2600 1790
6 1 2 1 1 3170 4404 1234
Parotid MRI findings were visually evaluated and classified into five grades (grade 0, 1, 2, 3, and 4) according to the methods reported previously by our
group [24]. LSG, labial salivary gland.
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Importantly, the grade of parotid MRI at 0 week correlated
significantly with the Greenspan grade of LSG biopsy at
baseline (Spearman’s rank correlation coefficient ¼ 0.822,
p50.05) (Table 2). However, changes in the grade of parotid
MRI did not correlate with those in salivary secretion by
Saxon’s test from 0 to 52 weeks (Spearman’s rank correlation
coefficient ¼ 0.169, p¼ 0.749) (Table 2). These results suggest
the effectiveness of abatacept for dryness, secretory
Figure 6. Correlation between improvement of SS and RA manifestations. Correlation between (A) increase in saliva volume (assessed by Saxon’s test)
and improvement in SDAI (n¼ 34) from baseline to 24 weeks. Spearman’s rank correlation coefficient ¼ 0.300, p¼ 0.085, and (B) between increase in
tear volume (assessed by Schirmer’s test) and improvement in SDAI (n¼ 30) from baseline to 24 weeks. Spearman’s rank correlation coefficient ¼
0.287, p¼ 0.124. Correlation between (C) the ratio of increase in saliva volume to baseline value (the increase in saliva volume from baseline to 24
weeks/saliva volume at baseline) and the ratio of improvement in SDAI to baseline value (the improvement in SDAI from baseline to 24 weeks/SDAI at
baseline) (n¼ 34). Spearman’s rank correlation coefficient ¼ 0.347, p¼ 0.044, and (D) between the ratio of increase in tear volume to baseline value (the
increase in tear volume from baseline to 24 weeks/tear volume at baseline) and the ratio of improvement in SDAI to baseline value (n¼ 27). Spearman’s
rank correlation coefficient ¼ 0.220, p¼ 0.270. Data deficit was compensated by the LOCF method.
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dysfunction, and suppression of salivary gland destruction in
patients with secondary SS with RA.
Effect of abatacept for immunological features
Treatment with abatacept resulted in significant reductions in
serum IgG and RF levels from 1805± 525mg/dl and 185±
270 IU/ml at 0 week to 1621± 415mg/dl and 167± 268 IU/ml at
24 weeks, respectively (p50.05) (Figure 5A and B). None of the
patients had hypogammaglobulinemia with IgG level5700mg/dl
during the 24 weeks. However, abatacept had no effect on anti-SS-
A antibody titer (Figure 5C). These findings suggest that abatacept
inhibits the production of some antibodies.
Correlation between improvement of SS and RA
manifestations
There was no significant correlation between the increase in saliva
volume by Saxon’s test and the improvement in SDAI from
baseline to 24 weeks (Spearman’s rank correlation coefficient ¼
0.300, p¼ 0.085, n¼ 34) (Figure 6A), nor between the increase in
tear volume by Schirmer’s test and improvement in SDAI from
baseline to 24 weeks (Spearman’s rank correlation coefficient ¼
0.287, p¼ 0.124, n¼ 30) (Figure 6B). Interestingly, the ratio of
increase in saliva volume to baseline value (the increase in saliva
volume from baseline to 24 weeks/saliva volume at baseline)
significantly correlated with the ratio of improvement in SDAI to
baseline value (the improvement in SDAI from baseline to 24
weeks/SDAI at baseline) (Spearman’s rank correlation coefficient
¼ 0.347, p¼ 0.044, n¼ 34) (Figure 6C). However, there was no
significant correlation between the ratio of increase in tear volume
to baseline value (the increase in tear volume from baseline to 24
weeks/tear volume at baseline) and the ratio of improvement in
SDAI to baseline value (Spearman’s rank correlation coefficient ¼
0.220, p¼ 0.270, n¼ 27) (Figure 6D). Saliva volume and SDAI
improved simultaneously in 17 of 34 (50.0%) patients, and tear
volume and SDAI in 15 of 30 (50.0%) patients from baseline to
24 weeks.
Adherence and safety of abatacept
The adherence rate to abatacept was 80.6% (29/36) for 52 weeks
(Figure 7). Seven patients dropped out before completion of the
52-week study. The reasons for dropout were adverse events in
two patients (at 0 and 36 weeks), inadequate effects in two patients
(at 24 and 48 weeks), economic reasons in one patient (at 40
weeks), and hospital transfer in two patients (both at 2 weeks).
Twelve AEs were recorded in 10 of 36 patients (27.8%) over
the period of 52 weeks, and 7 of these events (58.3%) were
infections. AEs occurred between 0 and 48 weeks, and all 12
required treatment, including admission to the hospital in 3
patients. Importantly, 7 of 12 AEs (58.3%) and 4 of 7 infections
(57.1%) occurred under corticosteroids use. During these compli-
cations, abatacept was withheld in four patients, and discontinued
in two patients (Table 3).
Discussion
In the present open-labeled, prospective, 1-year, and observational
multicenter study (ROSE trial), we confirmed the effectiveness of
abatacept for both SS and RA manifestations of secondary SS with
RA, as previously demonstrated by the interim analysis of 32
patients for 24 weeks of ROSE trial [20]. The study established the
clinical usefulness of abatacept with regard to the following five
aspects.
First, we proposed that abatacept is a promising therapeutic
option for RA manifestations in patients with secondary SS with
RA. In the present study, we demonstrated that 33.3% of patients
with established long-standing moderately active RA associated
with secondary SS, the majority (75%) of whom showed
inadequate response to MTX, were able to achieve remission
(by SDAI) for 52 weeks after the commencement of treatment
with abatacept. Especially, in 29 bio-naı¨ve patients, the remission
rate was 37.9% (11/29 patients) at 52 weeks, compared with 14.3%
in 7 bio-switch patients. A previous meta-analysis study that
Table 3. Adverse events in 36 cases during 52 weeks.
Case Adverse events Onset
(weeks)
Corticosteroids use
(equivalent PSL, mg/day)
Treatment
required?
Admission Administration
of ABT
Outcome
1 Urinary tract infection 7 5 + + Cessation Recovery
2 Urticaria 0 None +  Continue Recovery
3 Skin rash 0 3 +  Discontinue Recovery
4 Infectious cornea ulcer 24 2.5 +  Continue Recovery
5 Compression fracture of lumbar spine 12 5 + + Cessation Recovery
6 Bronchitis 4 3.75 +  Cessation Unknown*
7 Herpes zoster 4 None +  Continue Recovery
8 Vomit and diarrhea 8 5 +  Cessation Recovery
9 Sinusitis 36 7 +  Discontinue Un-recovery
10 Upper respiratory tract infection 22 None +  Continue Recovery
Pharyngitis 32 None + + Continue Recovery
Stomatitis 48 None +  Continue Recovery
PSL, prednisolone; ABT, abatacept; +, yes; , No.
*Unknown because of hospital transfer.
Figure 7. Adherence to abatacept. The adherence rate to abatacept
analyzed by Kaplan–Meier method was 80.6% (29/36) for 52 week.
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examined the effectiveness of abatacept combined with MTX
against active RA, reported that the remission rate, defined by
DAS28-ESR52.6, was 40.2% (95% confidence interval: 10.4–
80.3%) [25]. Thus, the remission rate in our study seems to be
comparable with that of previous studies on similar RA patients.
Interestingly, a recent study showed that RA patients with
secondary SS developed more severe arthritis and higher RA
disease activity than those without secondary SS [26]. Another
study showed that the presence of anti-SS-A antibody and
secondary SS in patients with RA could lower clinical response
to TNF inhibitors [27]. The latter study reported that the EULAR
responder (good or moderate) rate in RA patients with secondary
SS or anti-SS-A antibody was significantly lower (63% in
secondary SS and 58% in anti-SS-A antibody-positive patients)
than in those without secondary SS or anti-SS-A antibody (82%
and 83%, respectively) [27]. In the present study, we demonstrated
that abatacept was effective even for RA involvement in most
(82.9%) patients with RA and secondary SS who were positive for
anti-SS-A antibody with a high adherence rate for 52 weeks,
though such patients are considered to have severe disease and are
often resistant to TNF inhibitors. Our previous interim report [20]
and this extended report of ROSE trial are the first to investigate
the effectiveness of biologics in RA with secondary SS.
Second, our results demonstrated that abatacept improved
salivary and lacrimal secretory dysfunction in SS in a large
number of patients (34 patients for saliva volume and 30 patients
for tear volume) compared with previous studies [18–20]. To date,
only two open-labeled prospective single-arm studies using
abatacept for treatment of SS patients have been published,
excluding our ROSE trial, and no RCT has been reported. The first
study by Adler et al. [18] showed that abatacept significantly
reduced salivary gland inflammation and serum gamma globulin
levels, and increased saliva production when adjusted for disease
duration in 11 primary SS patients for 24 weeks. The next study by
Meiners et al. [19] (Active Sjo¨gren Abatacept Pilot study; ASAP
study) reported that ESSDAI, ESSPRI, RF, and IgG levels
decreased significantly during 24-week abatacept treatment and re-
increased in post-treatment phase in 15 patients with early and
active primary SS. With regard to glandular involvement,
abatacept treatment did not change salivary and lacrimal gland
functions, though a significant decrease in salivary flow was noted
after the completion of treatment [19]. Our study is unique relative
to the above two studies in that we assessed a larger number of
patients with secondary SS and RA, and our results showed that
abatacept improved both salivary and lacrimal functions as well as
subjective sicca symptoms. Importantly, saliva volume was
significantly increased by abatacept but this was only noted in
patients with Greenspan grade 1 or 2 of LSG biopsy but not in
those with grade 3 or 4. These observations indicate that early
intervention with abatacept against glandular manifestations is
important for the recovery of the secretory function in SS patients,
adding support to the report of Adler et al. [18].
Third, the ratio of increase in saliva volume to baseline value
significantly correlated with the ratio of improvement in SDAI to
baseline value. Moreover, both secretory function and SDAI
improved simultaneously in 50% of our patients. These findings
suggest that T cells play a common pathogenic role in the
development of SS and RA, indicating that abatacept is an ideal
therapeutic strategy for secondary SS with RA, ala ‘‘kill two birds
with one stone’’.
Fourth, abatacept suppressed antibody production, such as IgG
and RF in secondary SS with RA, in agreement with the above two
studies [18,19]. Moreover, a recent study showed that abatacept
reduced signs of polyclonal B cell activation in RA patients,
inducing a trend toward normalization of serum levels of different
classes of immunoglobulins and free light chains, decreasing titers
of anti-citrullinated protein antibodies and RF, and percentages of
post-switch memory B cells [28]. Thus, abatacept seems a logical
treatment for SS, in which activated B cell as well as T cells play
important pathogenic roles [16].
Fifth, no unexpected serious AEs were encountered in the
present study, and abatacept seems to be well tolerated in patients
with secondary SS with RA. Notably, infections should be
regarded among the AEs, similar to RA patients. More than half of
AEs and infections occurred under corticosteroids use in this
study, thus we should pay enough attention to these patients.
Moreover, we suggest that abatacept might suppress salivary
gland destruction in patients with SS. However, we assessed only
six cases by parotid MRI (four cases with no change, one case
with deterioration, and the other with improvement) without
control group in this study. There has been no report showing the
progression of salivary destruction in SS using MRI in the
longitudinal studies to the best of our knowledge. Thus, we need to
compare the progression of salivary destruction by MRI between
the abatacept treated group and the control group in the future
study, to confirm the effectiveness of abatacept on inhibition of
salivary destruction.
In conclusion, the present study highlighted the potential
therapeutic usefulness of abatacept for both RA and SS manifest-
ations of secondary SS with RA. Importantly, early intervention
against glandular involvement might be necessary for proper
recovery of secretory function in SS patients. The results need to
be confirmed in a larger cohort study and in RCTs that include
placebo groups using newly proposed composite disease activity
measures such as ESSDAI and ESSPRI.
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